News
AEON
0.2408
-5.46%
-0.0139
Weekly Report: what happened at AEON last week (0824-0828)?
Weekly Report · 08/31 10:01
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 08/27 17:06
Aeon Biopharma designates Paul Lee as acting chief regulatory officer
TipRanks · 08/24 12:10
AEON Biopharma Designates Paul Lee As Chief Regulatory Office
Benzinga · 08/24 12:05
Press Release: AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer
Dow Jones · 08/24 12:00
Weekly Report: what happened at AEON last week (0817-0821)?
Weekly Report · 08/24 10:01
Major Investor Quietly Makes Bold Move Into AEON Biopharma Stock
TipRanks · 08/22 02:01
Analysts Offer Insights on Healthcare Companies: AEON Biopharma (AEON), BioMarin Pharmaceutical (BMRN) and Immatics (IMTX)
TipRanks · 08/19 13:40
AEON Reports Expanded Structural Data Supporting Molecular Similarity Of ABP-450 To BOTOX
NASDAQ · 08/19 12:54
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 08/19 12:07
AEON Biopharma Announces Final, Expanded Primary Structure Results And Preliminary Disulfide Bond Characterization Data Providing Complementary Evidence Supporting Molecular Similarity Of ABP-450 To BOTOX
Benzinga · 08/19 12:02
Weekly Report: what happened at AEON last week (0810-0814)?
Weekly Report · 08/17 10:02
Aeon Biopharma price target lowered to $1.20 from $5 at H.C. Wainwright
TipRanks · 08/16 12:58
AEON Biopharma Price Target Cut to $1.20/Share From $5.00 by HC Wainwright & Co.
Dow Jones · 08/14 17:42
AEON Biopharma Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 08/14 17:42
HC Wainwright & Co. Maintains Buy on AEON Biopharma, Lowers Price Target to $1.2
Benzinga · 08/14 17:32
Analysts Offer Insights on Healthcare Companies: AEON Biopharma (AEON) and Immix Biopharma (IMMX)
TipRanks · 08/14 15:50
AEON Biopharma Q2 Non-GAAP EPS of -$0.02
Seeking Alpha · 08/13 14:25
AEON Biopharma Reports Q2 Results, Advances ABP-450 Program
TipRanks · 08/12 20:56
AEON Biopharma Q2 EPS $(0.02) Beats $(0.12) Estimate
Benzinga · 08/12 20:34
More
Webull provides a variety of real-time AEON stock news. You can receive the latest news about Aeon Biopharma through multiple platforms. This information may help you make smarter investment decisions.
About AEON
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed enrollment and dosing of patients for a Phase II double blind study of ABP-450 for the treatment of both chronic and episodic migraine.